GlassScriptPhysician profile
Amanda Charpentier
NPI 1700458015
$2,492.07
in general payments reported to CMS, 2019-2025
24 companies · $2,148 in 2025
The $2,148 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $154 · 2023: $15.47 · 2024: $174 · 2025: $2,148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,338.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,337.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acadia Pharmaceuticals INC | $309.27 | 2025 | Nuplazid |
| Ucb, INC. | $305.44 | 2024-2025 | Briviact, Nayzilam, Rystiggo |
| Abbvie INC. | $254.35 | 2024-2025 | |
| Pfizer INC. | $226.45 | 2025 | |
| Lilly USA, LLC | $209.90 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Lundbeck LLC | $207.87 | 2025 | Vyepti |
| Eisai INC. | $147.27 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $140.47 | 2022-2023 | |
| Biogen, INC. | $127.74 | 2025 | Leqembi, Vumerity, Skyclarys |
| Csl Behring | $96.58 | 2024-2025 | Hizentra |
| Novartis Pharmaceuticals Corporation | $90.37 | 2025 | |
| Axsome Therapeutics, INC. | $84.64 | 2024-2025 | Symbravo, Sunosi |
| Neurocrine Biosciences, INC. | $60.00 | 2025 | |
| Merz Pharmaceuticals, LLC | $37.03 | 2025 | Xeomin, Inbrija, Ampyra |
| Emd Serono, INC. | $32.83 | 2024-2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $25.00 | 2025 | |
| Cycle Pharmaceuticals INC | $23.07 | 2025 | Tascenso Odt |
| Amneal Pharmaceuticals LLC | $20.00 | 2025 | Crexont |
| Aucta Pharmaceuticals, INC. | $18.04 | 2024 | Motpoly Xr |
| Alexion Pharmaceuticals, INC. | $16.67 | 2025 | Ultomiris |
| Genentech USA, INC. | $16.67 | 2025 | Ocrevus Zunovo |
| Janssen Biotech, INC. | $16.22 | 2025 | |
| Averitas Pharma INC. | $14.63 | 2025 | Qutenza |
| Amgen INC. | $11.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Charpentier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.